Roche Chairman still expects diagnostic products to be impacted by US tariffs

Gelonghui, March 7th｜Roche Group Chairman Severin Schwan stated on Saturday that Roche expects its agreement with the US government will exempt its pharmaceuticals from the current round of import tariffs. However, its diagnostics division still faces risks and may be subject to new tariffs after the initial 150-day period expires. Schwan said that Roche's diagnostics division had sales close to 14 billion Swiss francs in 2025, with most of its tests and instruments exported to the US from Switzerland and other European countries.